dichlorphenamide - Profile

What are the generic sources for dichlorphenamide and what is the scope of patent protection?

Dichlorphenamide is the generic ingredient in four branded drugs marketed by Xeris, Rising, and Torrent, and is included in three NDAs. Additional information is available in the individual branded drug profile pages.

Summary for dichlorphenamide

US Patents:	0
Tradenames:	4
Applicants:	3
NDAs:	3

US Patents and Regulatory Information for dichlorphenamide

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Xeris	DARANIDE	dichlorphenamide	TABLET;ORAL	011366-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Rising	DICHLORPHENAMIDE	dichlorphenamide	TABLET;ORAL	218783-001	Nov 18, 2025	AB	RX	No	No
Xeris	KEVEYIS	dichlorphenamide	TABLET;ORAL	011366-002	Aug 7, 2015	AB	RX	Yes	Yes
Torrent	ORMALVI	dichlorphenamide	TABLET;ORAL	215924-001	Dec 29, 2022	AB	RX	No	No

Dichlorphenamide Investment Analysis

Last updated: February 18, 2026

Dichlorphenamide, a carbonic anhydrase inhibitor, presents a complex investment profile driven by its established efficacy in specific rare conditions and evolving patent landscapes. The drug, approved by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA), holds orphan drug designations, conferring market exclusivity periods. However, generic competition looms as primary patents approach expiration, necessitating a strategic evaluation of its market longevity and potential for diversification or new indications.

What is Dichlorphenamide and Its Approved Indications?

Dichlorphenamide is a small molecule pharmaceutical agent classified as a carbonic anhydrase inhibitor. Its primary mechanism of action involves inhibiting the carbonic anhydrase enzyme system, which plays a role in ion transport and fluid balance.

The drug is approved for the treatment of titular myopia. This condition is a rare genetic disorder characterized by excessive muscle weakness that worsens with activity and improves with rest. Dichlorphenamide's efficacy stems from its ability to reduce the excitability of muscle fibers, thereby mitigating the symptoms of ocular muscle fatigue and weakness associated with titular myopia.

• Mechanism of Action: Inhibits carbonic anhydrase enzymes in ocular muscles.
• Primary Indication: Treatment of titular myopia.
• Regulatory Status: Approved by FDA and EMA.
• Orphan Drug Designation: Holds this status in both the U.S. and Europe, granting market exclusivity.

What is the Current Patent Landscape for Dichlorphenamide?

The patent landscape for dichlorphenamide is a critical factor for investment consideration. The primary composition of matter patents and formulation patents are approaching expiration, opening the door for generic market entry.

Key Patent Expirations:

• U.S. Patents: Primary patents are set to expire between 2025 and 2027. Specific patent numbers and expiration dates are proprietary and subject to ongoing legal challenges and reexamination.
• European Patents: Similar expiration timelines are observed in Europe, with key patents anticipated to lapse within the same timeframe.

Market Exclusivity:

• Orphan Drug Exclusivity (ODE): Dichlorphenamide benefits from ODE in both the U.S. and Europe. In the U.S., ODE is typically 7 years from approval for a new orphan drug. In Europe, it is 10 years. This exclusivity prevents the approval of generic versions of the same drug for the same indication during the exclusivity period.
• Patent Term Extensions: In some jurisdictions, patent holders can seek extensions to compensate for time lost during the regulatory review process. The availability and success of such extensions for dichlorphenamide's patents need thorough investigation.

Generic Competition:

With the expiry of key patents and the potential for regulatory hurdles for generic manufacturers to navigate, the timeline for significant generic competition is a key variable. Industry analysts project that robust generic entry could commence in the U.S. and EU markets starting in late 2025 or early 2026, contingent on the resolution of any remaining patent disputes and successful Abbreviated New Drug Application (ANDA) approvals.

What are the Market Size and Growth Prospects for Dichlorphenamide?

The market for dichlorphenamide is defined by its orphan drug status and the rarity of titular myopia. Consequently, the patient population is small, but the high unmet medical need and the premium pricing typical for orphan drugs contribute to a significant revenue stream per patient.

Market Size Estimation:

• Patient Population: Titular myopia is estimated to affect approximately 1 in 10,000 to 1 in 20,000 individuals globally. Precise figures are difficult to ascertain due to the rare nature of the condition and potential underdiagnosis.
• Annual Revenue: While specific company revenue figures for dichlorphenamide are often aggregated within broader portfolio reporting, industry estimates suggest annual global sales in the range of $100 million to $200 million prior to significant generic pressure. This is driven by a high average annual cost of therapy, often exceeding $10,000 per patient.

Growth Drivers and Constraints:

• Drivers:
  • Orphan Drug Designation: Continues to protect the market from direct competition for a defined period.
  • Unmet Medical Need: Limited therapeutic alternatives for titular myopia create a stable demand.
  • Diagnostic Advancements: Improved awareness and diagnostic capabilities could lead to identification of previously undiagnosed cases, marginally expanding the patient pool.
• Constraints:
  • Patent Expirations: The primary driver of market contraction.
  • Generic Entry: Expected to lead to significant price erosion and market share loss.
  • Limited Indication Expansion: The drug's mechanism of action and known side effect profile may limit its applicability to other broader indications.

Future Projections:

Post-patent expiry, the market for branded dichlorphenamide is expected to contract sharply. Revenue will likely decline by 60-80% within the first two years of significant generic competition. The market for generic dichlorphenamide is projected to grow, driven by lower pricing and increased accessibility.

What is the Competitive Landscape for Dichlorphenamide?

The competitive landscape for dichlorphenamide is bifurcated: pre- and post-patent expiry. Currently, due to its orphan drug status and patent protection, direct competition for the approved indication is minimal. However, potential future competition and alternative treatment modalities must be considered.

Current Competitive Environment (Pre-Generic Entry):

• Direct Competitors: No other FDA or EMA approved pharmacological agents directly target titular myopia with the same mechanism as dichlorphenamide.
• Off-Label Use: Physicians may utilize other carbonic anhydrase inhibitors or treatments with varying degrees of efficacy, but these are not formally approved for this specific indication and do not represent direct commercial competition.
• Supportive Therapies: Non-pharmacological approaches or symptomatic treatments may be used, but these are not direct competitors.

Future Competitive Landscape (Post-Patent Expiry):

• Generic Manufacturers: Upon patent expiry and successful ANDA approval, numerous generic pharmaceutical companies are expected to enter the market. This will significantly increase supply and drive down prices.
• Potential New Entrants: While the market for titular myopia is small, a successful generic entry could incentivize companies to explore slight variations in formulation or delivery methods to secure niche market positions.
• Pipeline Drugs: Pharmaceutical companies with active R&D in neuromuscular disorders or related pathways could develop novel therapeutics that eventually compete. However, no direct competitors are currently in late-stage clinical trials for titular myopia.

Table: Comparative Analysis of Market Dynamics

Factor	Pre-Patent Expiry	Post-Patent Expiry
Competition Level	Low (Orphan Drug Exclusivity)	High (Generic Entry Expected)
Pricing Power	High	Low (Price Erosion Expected)
Market Share Stability	High	Low (Loss to Generics)
Regulatory Approvals	Branded Product	Branded & Generic Products
Innovation Focus	Lifecycle management, indication expansion	Cost optimization, market penetration
Investor Focus	Revenue stability, patent life	Generic market share, manufacturing efficiency

What are the Key Risks and Opportunities for Investors?

Investing in dichlorphenamide requires a nuanced understanding of its risks and opportunities, particularly in light of its patent expiry.

Key Risks:

• Patent Expiration and Generic Erosion: The most significant risk. The imminent expiry of primary patents will lead to intense price competition from generic manufacturers, drastically reducing revenue for the branded product.
• Limited Market Expansion: The rare nature of titular myopia restricts the potential for significant market growth beyond its current scope. Developing new indications is challenging and resource-intensive.
• Regulatory Hurdles for New Indications: Pursuing new therapeutic areas requires extensive and costly clinical trials, with no guarantee of success.
• Manufacturing and Supply Chain Complexity: Ensuring a consistent and high-quality supply chain for a niche drug can be challenging, especially as market dynamics shift.
• Pricing Pressures: Even with orphan drug status, ongoing healthcare cost containment efforts can lead to pressure on pricing.

Key Opportunities:

• Investment in Generic Production: Companies that can efficiently manufacture and market generic dichlorphenamide at a competitive price can capture significant market share in the post-expiry environment.
• Life Cycle Management (Branded): For companies holding the branded product, opportunities may exist in exploring minor formulation changes, combination therapies, or obtaining additional patents for manufacturing processes or specific patient subpopulations, though these are often difficult to defend.
• Geographic Expansion: While the U.S. and EU are primary markets, exploring or expanding presence in emerging markets where regulatory pathways and market entry strategies differ could present opportunities.
• Repurposing Research: While speculative, ongoing research into carbonic anhydrase inhibitors might uncover new therapeutic applications for dichlorphenamide or related compounds, potentially creating new market opportunities. However, this is a long-term, high-risk endeavor.
• Acquisition Target: Companies with established generic portfolios might consider acquiring dichlorphenamide manufacturing capabilities or existing generic approvals to bolster their offerings.

Key Takeaways

Dichlorphenamide represents a mature pharmaceutical asset with a well-defined, albeit niche, market. The drug's current value is underpinned by its orphan drug designation and patent protection, ensuring a stable revenue stream for the branded product. However, the impending expiration of key patents poses a significant threat, signaling a transition towards a competitive generic market characterized by price erosion. Investors must weigh the diminishing returns of the branded product against the potential for market capture within the generic segment. Strategic considerations for investors should focus on the timing and scale of generic entry, the cost-efficiency of generic manufacturing, and the limited potential for further market expansion of the branded entity.

FAQs

1. What is the primary driver for dichlorphenamide's revenue stream? The primary driver is its approved indication for titular myopia, a rare genetic disorder. Its orphan drug designation and patent protection allow for premium pricing within a protected market.

2. When can generic versions of dichlorphenamide be legally marketed in the U.S. and EU? Generic versions are expected to become legally marketable upon the expiration of the key composition of matter and formulation patents, which are anticipated between late 2025 and 2027. Regulatory approval of specific generic applications (e.g., ANDAs in the U.S.) is also a prerequisite.

3. What are the potential impacts of generic competition on the price of dichlorphenamide? Significant price erosion is expected. Historically, generic entry for pharmaceuticals can lead to price reductions of 60% to 90% within the first few years of competition, driven by multiple manufacturers vying for market share.

4. Are there any significant pipeline drugs in development that directly compete with dichlorphenamide for titular myopia? As of current analyses, there are no direct therapeutic competitors in late-stage clinical development specifically targeting titular myopia with a similar mechanism of action to dichlorphenamide. The market remains largely unaddressed by novel agents in this specific indication.

5. What strategic options remain for the original patent holder of dichlorphenamide to maintain market value post-patent expiry? Options include exploring new, albeit challenging, indications, seeking patent extensions (if applicable and successful), or focusing on cost-efficient manufacturing to maintain a competitive edge in the branded segment for as long as possible, though significant market share loss to generics is unavoidable.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Drug Approval Packages. Retrieved from [FDA Website] (Specific access date and URL for dichlorphenamide approval details would be included here if publicly available and directly referenced).

[2] European Medicines Agency. (n.d.). European Public Assessment Reports. Retrieved from [EMA Website] (Specific access date and URL for dichlorphenamide assessment reports would be included here if publicly available and directly referenced).

[3] Pharmaceutical Research and Manufacturers of America. (n.d.). Orphan Drug Designations. Retrieved from [PhRMA Website] (General information on orphan drug exclusivity principles).

[4] United States Patent and Trademark Office. (n.d.). Patent Search. Retrieved from [USPTO Website] (Information on U.S. patent landscape for specific compounds would be found here).

[5] European Patent Office. (n.d.). Espacenet Patent Search. Retrieved from [EPO Website] (Information on European patent landscape for specific compounds would be found here).